Delinking the cost of R&D from the final prices of medicines and making governments the funders and planners of drug development would be rife with problems.
March 4, 2019
Misusing the “march-in right” provision of the Bayh-Dole Act could negatively impact U.S. life-sciences innovation and result in fewer new drugs.
February 25, 2019
A new study has sought to quantify this impact, tracking the availability of drugs released after 1981 that are designed to treat 66 diseases across 27 countries.
December 31, 2018
Comments to the Centers for Medicare & Medicaid Services on an International Pricing Index Model for Medicare Part B Drugs
Adopting an international drug reference pricing scheme would limit drug innovation—potentially leading to higher, not lower, health care costs in the future—while at the same time reducing U.S. biopharmaceutical industry competitiveness, meaning fewer jobs and exports.
December 20, 2018
While many medical interventions—from vaccines, anesthesia, antibiotics, and even eyeglasses—have initially seemed like playing god, interventions to manipulate directly the heritable genetic endowment fundamental not only to what makes us human, but to what makes each of us unique, had never been seen before.
November 15, 2018
Stephen Ezell gave the keynote presentation at the Life Sciences Tennessee Annual Conference on innovation economics and how smart public policies can stimulate Tennessee’s growing life-sciences innovation sector.
November 10, 2018
As Rob Atkinson writes for The Hill, price controls and other steps to reduce drug company revenues would stifle knowledge generation and sharing, leaving future generations less access to effective new drugs than would otherwise be the case.
November 5, 2018
A considerable share of biopharma research “spills over” and contributes to knowledge discovery and drug development overall, not just in individual firms’ labs.
September 24, 2018
Petition to the Food and Drug Administration Requesting a Stop to Deceptive and Misleading “Non-GMO” Food Labels
The Non-GMO Project food label deliberately deceives and misleads consumers in violation of the Federal Food, Drug and Cosmetic Act. ITIF petitions FDA to prohibit such labels.
September 13, 2018
ITIF's Center for Data Innovation will host a public forum with key stakeholders from government, the private sector, and academia to discuss the latest developments in using data to improve health care outcomes, reduce health care costs, and empower patients.
September 4, 2018
Debates over high-priced prescription drugs tend to focus on whether the government should attempt to constrict the pharmaceutical industry, whether by reducing patent protections or by mandating lower prices. What these conversations miss, though, is that drug prices could also fall through the expansion of the pharmaceutical industry, rather than its restriction.